These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 21940664)

  • 41. Exploring newer target sodium glucose transporter 2 for the treatment of diabetes mellitus.
    Vaidya HB; Goyal RK
    Mini Rev Med Chem; 2010 Sep; 10(10):905-13. PubMed ID: 21034414
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Localizations of Na(+)-D-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart.
    Vrhovac I; Balen Eror D; Klessen D; Burger C; Breljak D; Kraus O; Radović N; Jadrijević S; Aleksic I; Walles T; Sauvant C; Sabolić I; Koepsell H
    Pflugers Arch; 2015 Sep; 467(9):1881-98. PubMed ID: 25304002
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Biophysical characteristics of the pig kidney Na+/glucose cotransporter SGLT2 reveal a common mechanism for SGLT1 and SGLT2.
    Mackenzie B; Loo DD; Panayotova-Heiermann M; Wright EM
    J Biol Chem; 1996 Dec; 271(51):32678-83. PubMed ID: 8955098
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Interaction of the Sodium/Glucose Cotransporter (SGLT) 2 inhibitor Canagliflozin with SGLT1 and SGLT2.
    Ohgaki R; Wei L; Yamada K; Hara T; Kuriyama C; Okuda S; Ueta K; Shiotani M; Nagamori S; Kanai Y
    J Pharmacol Exp Ther; 2016 Jul; 358(1):94-102. PubMed ID: 27189972
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of dapagliflozin on colon cancer cell [Rapid Communication].
    Saito T; Okada S; Yamada E; Shimoda Y; Osaki A; Tagaya Y; Shibusawa R; Okada J; Yamada M
    Endocr J; 2015; 62(12):1133-7. PubMed ID: 26522271
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dual inhibition of sodium-glucose linked cotransporters 1 and 2 exacerbates cardiac dysfunction following experimental myocardial infarction.
    Connelly KA; Zhang Y; Desjardins JF; Thai K; Gilbert RE
    Cardiovasc Diabetol; 2018 Jul; 17(1):99. PubMed ID: 29981571
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Conformational dynamics of hSGLT1 during Na+/glucose cotransport.
    Loo DD; Hirayama BA; Karakossian MH; Meinild AK; Wright EM
    J Gen Physiol; 2006 Dec; 128(6):701-20. PubMed ID: 17130520
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Identification of an oxime-containing C-glucosylarene as a potential inhibitor of sodium-dependent glucose co-transporter 2.
    Yuan MC; Yeh TK; Chen CT; Song JS; Huang YC; Hsieh TC; Huang CY; Huang YL; Wang MH; Wu SH; Yao CH; Chao YS; Lee JC
    Eur J Med Chem; 2018 Jan; 143():611-620. PubMed ID: 29216560
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Design, synthesis and biological evaluation of 6-deoxy O-spiroketal C-arylglucosides as novel renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.
    Wang Y; Lou Y; Wang J; Li D; Chen H; Zheng T; Xia C; Song X; Dong T; Li J; Li J; Liu H
    Eur J Med Chem; 2019 Oct; 180():398-416. PubMed ID: 31325786
    [TBL] [Abstract][Full Text] [Related]  

  • 50. High affinity phlorizin receptor sites and their relation to the glucose transport mechanism in the proximal tubule of dog kidney.
    Silverman M; Black J
    Biochim Biophys Acta; 1975 Jun; 394(1):10-30. PubMed ID: 1095065
    [TBL] [Abstract][Full Text] [Related]  

  • 51. 5,5-Difluoro- and 5-Fluoro-5-methyl-hexose-based C-Glucosides as potent and orally bioavailable SGLT1 and SGLT2 dual inhibitors.
    Xu G; Du F; Kuo GH; Xu JZ; Liang Y; Demarest K; Gaul MD
    Bioorg Med Chem Lett; 2020 Sep; 30(17):127387. PubMed ID: 32738984
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Structural Basis of the Selective Sugar Transport in Sodium-Glucose Cotransporters.
    Kamitori K; Shirota M; Fujiwara Y
    J Mol Biol; 2022 Mar; 434(5):167464. PubMed ID: 35077764
    [TBL] [Abstract][Full Text] [Related]  

  • 53. What does sodium-glucose co-transporter 1 inhibition add: Prospects for dual inhibition.
    Dominguez Rieg JA; Rieg T
    Diabetes Obes Metab; 2019 Apr; 21 Suppl 2(Suppl 2):43-52. PubMed ID: 31081587
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of SGLT2 inhibition in human kidney proximal tubular cells--renoprotection in diabetic nephropathy?
    Panchapakesan U; Pegg K; Gross S; Komala MG; Mudaliar H; Forbes J; Pollock C; Mather A
    PLoS One; 2013; 8(2):e54442. PubMed ID: 23390498
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In vitro-in vivo correlation of the inhibition potency of sodium-glucose cotransporter inhibitors in rat: a pharmacokinetic and pharmacodynamic modeling approach.
    Yamaguchi K; Kato M; Suzuki M; Hagita H; Takada M; Ayabe M; Aso Y; Ishigai M; Ikeda S
    J Pharmacol Exp Ther; 2013 Apr; 345(1):52-61. PubMed ID: 23386251
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level.
    Katsuno K; Fujimori Y; Takemura Y; Hiratochi M; Itoh F; Komatsu Y; Fujikura H; Isaji M
    J Pharmacol Exp Ther; 2007 Jan; 320(1):323-30. PubMed ID: 17050778
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Targeting renal glucose reabsorption for the treatment of type 2 diabetes mellitus using the SGLT2 inhibitor dapagliflozin.
    Jabbour SA; Whaley JM; Tirmenstein M; Poucher SM; Reilly TP; Boulton DW; Saye J; List JF; Parikh S
    Postgrad Med; 2012 Jul; 124(4):62-73. PubMed ID: 22913895
    [TBL] [Abstract][Full Text] [Related]  

  • 58. TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity.
    Yamamoto K; Uchida S; Kitano K; Fukuhara N; Okumura-Kitajima L; Gunji E; Kozakai A; Tomoike H; Kojima N; Asami J; Toyoda H; Arai M; Takahashi T; Takahashi K
    Br J Pharmacol; 2011 Sep; 164(1):181-91. PubMed ID: 21410690
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dapagliflozin, an oral sodium glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus.
    Calado J
    IDrugs; 2009 Dec; 12(12):785-98. PubMed ID: 19943222
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phenylglucosides and the Na+/glucose cotransporter (SGLT1): analysis of interactions.
    Lostao MP; Hirayama BA; Loo DD; Wright EM
    J Membr Biol; 1994 Nov; 142(2):161-70. PubMed ID: 7884808
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.